Recordati Industria Chimica e Farmaceutica SPA (IT:REC) has released an update. Recordati Industria Chimica e Farmaceutica SPA reported strong ...

Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.

(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...

New drug Enjaymo recorded sales of €28 million in the quarter compared with €26 million in the previous quarter. Sanofi has sold global rights to Enjaymo to Recordati. The transaction is ...

Sanofi (NASDAQ:SNY) shares gained on Friday after the French pharma giant exceeded analysts' estimates with its Q3 thanks mainly to earlier-than-anticipated vaccine sales and a 22% YoY rise in ...

In sustained rare disease push, Recordati lays out $825M upfront to acquire Sanofi's CAD drug Enjaymo Meanwhile, Sanofi saw revenues for its consumer health arm, Opella, grow 7.9%. Earlier this ...

Sanofi expects a low single-digit decline in flu shot sales due to the soft vaccination rate. Sanofi reaffirms that Dupixent will deliver around 13 billion euros in 2024 sales. The company ...

Agomab Ther­a­peu­tics is ben­e­fit­ing from Sanofi’s push to be­come an im­munol­o­gy pow­er­house.

(Reuters) - French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than-anticipated start of the vaccination season.

Sanofi reported a 25% boost in sales for its vaccines division during the third quarter, helped by earlier-than-anticipated orders of its flu shots as well as rising revenue from Beyfortus, its RSV ...

Leerink Partners analyst David Risinger in a Friday note to investors said Sanofi expects Q4 Beyfortus sales similar to Q3. Sanofi released its third-quarter earnings report on Friday, beating ...

(Bloomberg) -- After a year-long takeover battle for the owner of France’s best-selling painkiller, Sanofi’s decision to sell its over-the-counter business to a US buyout firm descended into ...